Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 2.425 1.04% 0.03
ACRX closed up 1.04 percent on Thursday, April 19, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ACRX trend table...

Date Alert Name Type % Chg
Apr 19 Spinning Top Other 0.00%
Apr 19 NR7 Range Contraction 0.00%
Apr 19 Upper Bollinger Band Walk Strength 0.00%
Apr 19 Inside Day Range Contraction 0.00%
Apr 19 Overbought Stochastic Strength 0.00%
Apr 18 200 DMA Resistance Bearish 1.04%
Apr 18 Doji - Bearish? Reversal 1.04%
Apr 18 Upper Bollinger Band Walk Strength 1.04%
Apr 18 Overbought Stochastic Strength 1.04%
Apr 18 Upper Bollinger Band Touch Strength 1.04%

Older signals for ACRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.75
52 Week Low 1.55
Average Volume 467,602
200-Day Moving Average 2.4995
50-Day Moving Average 2.0186
20-Day Moving Average 2.226
10-Day Moving Average 2.305
Average True Range 0.1117
ADX 45.4
+DI 26.75
-DI 4.46
Chandelier Exit (Long, 3 ATRs ) 2.1649
Chandelier Exit (Short, 3 ATRs ) 2.3351
Upper Bollinger Band 2.458
Lower Bollinger Band 1.994
Percent B (%b) 0.93
BandWidth 20.844564
MACD Line 0.1001
MACD Signal Line 0.0837
MACD Histogram 0.0164
Fundamentals Value
Market Cap 110.04 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -2.20
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.55
Resistance 3 (R3) 2.54 2.50 2.53
Resistance 2 (R2) 2.50 2.46 2.50 2.52
Resistance 1 (R1) 2.46 2.45 2.48 2.47 2.51
Pivot Point 2.42 2.42 2.42 2.42 2.42
Support 1 (S1) 2.38 2.38 2.40 2.39 2.34
Support 2 (S2) 2.34 2.37 2.34 2.33
Support 3 (S3) 2.30 2.34 2.33
Support 4 (S4) 2.31